Intracranial Hemorrhage Risk Associated With Thrombolytic Therapy in Ischemic Stroke: A Review

Ischemic stroke is a medical emergency caused by disrupted blood flow to the brain, leading to brain cell death. Thrombolytic agents like alteplase have been effective in treating acute ischemic stroke by breaking down blood clots. However, this treatment also poses the risk of intracranial hemorrhage (ICH). This review examines the incidence, risk factors, and management of ICH associated with thrombolytic therapy in ischemic stroke. The review discusses key clinical trials and meta-analyses that assess the risk of ICH with thrombolytic therapy. Scoring systems, such as the ICH Score and Essen ICH Score, are highlighted as tools for predicting ICH risk based on patient characteristics. Management and prevention strategies for ICH in thrombolytic therapy are explored, including careful blood pressure control, reversal of anticoagulation, and other interventions to reduce bleeding risk. Novel approaches involving neuroprotective agents like minocycline are also discussed as potential interventions to reduce secondary injury mechanisms after ICH. The review emphasizes the importance of individualized decision-making when considering thrombolytic therapy, weighing potential benefits against the risk of ICH for each patient. Clinical guidelines are outlined to aid clinicians in making informed treatment decisions. Overall, this review underscores the need for ongoing research to optimize patient selection and treatment strategies, with the ultimate goal of reducing complications and improving outcomes in ischemic stroke patients at risk of ICH associated with thrombolytic therapy.